Bulls Don't Want to Be Tardy to the Dance<br />By Rev Shark<br />RealMoney.com Contributor<br />6/25/2009 8:42 AM EDT <br /><br />A horse never runs so fast as when he has other horses to catch up and outpace. <br />-- Ovid<br /><br />Market action is becoming increasingly muddled as technical conditions slowly deteriorate, but hopes of an end-of-quarter window-dressing bounce keeps the bulls ready for action. Yesterday the pending FOMC interest rate decision helped to boost the market out of the gate, but the actual news, which contained nothing surprising, wasn't enough to keep the buyers interested. <br /><br />Although there were some pretty good bounces in select momentum stocks yesterday such as Netease.com (NTES) , Shanda (SNDA) , Green Mountain Coffee Roasters (GMCR) and Baidu (BIDU) , other key stocks like Apple (AAPL) , Research In Motion (RIMM) and Visa (V) are looking quite troubled. There is very little good momentum in this market, but there is a lot of money looking for some bounces into the end of the month, and they are always going to be attracted to some of the key high-beta names. Nothing drives money managers more than trying to catch up with other money managers. <br /><br />So we have a market that is looking troubled but we also have conditions that could easily drive some upside over the next four days of trading. One of the big problems with this scenario is that everyone is waiting for the quarter-end mark-ups. When everyone is looking for the same thing to occur it can become self-fulfilling, but it also can be extremely unstable as everyone tries to stay a step ahead of one another. When everyone is looking for an end-of-the-quarter move, they will rush to be in first and then rush to take gains first. The more they try to jump in front of each other, the more likely the move does not develop well. <br /><br />At this point we have some very weak technical support in the indices, most notably at 900 on the S&P 500. If we can continue to hold in this area we should have some forays on the upside in hopes of catching a quarter-end move. I suspect dip-buyers will even lend us some support should we begin to stumble, but the key is to not be too trusting of the upside here. <br /><br />Keep in mind that everyone is looking for that end-of-the-quarter bouncem but they aren't investing -- they are trading, and they'll be happy to take some quick gains if they can catch them. I'm looking for the market to hold up fairly well while the quarter winds down, but it is just a matter of time before we crack S&P 500 support around 878 or so and see another leg down. <br /><br />So let's see if we can catch some trades in the end-of-quarter circus, but let's make sure we keep in mind that the technical conditions are looking increasingly precarious and we'll need to be ready to move quickly to avoid being caught in some downside. We have a rather flat open shaping up with gold and oil showing a little strength. Europe was weak and Asia strong. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: HTZ +12.7%, BBBY +5.9% (also upgraded to Neutral from Underperform at Cowen), LEN +5.5%, CKR +3.4% (also reports period five same-store sales of -5.2%), JEF +3.3% (also filed for a mixed shelf offering for an indeterminate amount), STX +1.8% (also upgraded to Hold at Deutsche)... M&A news: AVGN +29.8% (MediciNova intends to acquire Avigen), TWB +21.2% and DBRN +4.2% (Tween Brands to be acquired by DBRN in all stock deal; TWB shareholders to receive equivalent of $6.22 per share based on 6/24 closing price)... Select shippers ticking higher: NM +5.1%, EGLE +2.3%, EXM +2.1%... Other news: JAZZ +34.5% (Jazz Pharma and UCB announce second Phase III study of sodium oxybate in patients with fibromyalgia meets primary endpoints), CAEI +32.8% (announces new contract to build resort near Shanghai; project value to exceed $500 mln), AGEN +15.8% (has expanded its Phase 2 clinical trial of Oncophage), IMAX +12.0% (underwriter has exercised in full its option to purchase an additional 1,470,000 common shares), DTG +6.2% (up in sympathy with HTZ), ARM +5.6% (divests ownership stakes in two light vehicle systems chassis businesses), OGXI +4.5% (continued strength from yesterday's ~10% pop), QGEN +4.0% (still checking), MDRX +3.6% (estimates that new order intake for its clinical solutions during Q3, was ~$103 mln vs $82 mln), HCBK +2.8% (Cramer makes positive comments on MadMoney)... Analyst comments: SLM +5.0% (upgraded to Overweight at JPMorgan), ADI +4.7% (upgraded to Buy from Underperform at BofA/Merrill), BIG +2.6% (upgraded to Outperform from Neutral at Cowen), PT +1.9% (raised to Buy from Neutral by Goldman Sachs- DJ), DE +1.4% (upgraded to Neutral from Sell at Goldman- DJ), RIG +1.4% (raised to Buy from Neutral at Goldman- Reuters), AA +1.2% (initiated with a Buy at Citigroup).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: SVU -10.8%, DRI -2.1%... Select European drug names showing weakness: NVS -2.2%, SNY -2.0%... Other news: LYG -13.8% (trading ex dividend), AGP -10.4% (discloses Q1 update; outpatient medical costs appear to be higher than previously estimated), PQ -10.2% (announces a 10 mln share common stock offering), RT -9.1% (still checking), OSIR -6.7% (reports interim data for COPD stem cell study; The trial met its primary goal of demonstrating the safety of Prochymal in patients), ROY -3.2% (to raise C$50 mln in bought deal financing), SWY -2.0% (trading down in sympathy with SVU)... Analyst comments: WFR -2.9% (downgraded to Underweight at JPMorgan), BA -1.3% (downgraded to Equal Weight from Overweight at Morgan Stanley and downgraded to Underperform at Oppenheimer).